Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. 1997

S N Finkelstein, and S L Huber, and P E Greenberg

UI MeSH Term Description Entries
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

S N Finkelstein, and S L Huber, and P E Greenberg
January 1997, The Annals of pharmacotherapy,
S N Finkelstein, and S L Huber, and P E Greenberg
November 1998, Anti-cancer drugs,
S N Finkelstein, and S L Huber, and P E Greenberg
November 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S N Finkelstein, and S L Huber, and P E Greenberg
November 1996, Cancer treatment reviews,
S N Finkelstein, and S L Huber, and P E Greenberg
July 1995, Medical and pediatric oncology,
S N Finkelstein, and S L Huber, and P E Greenberg
January 2000, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
S N Finkelstein, and S L Huber, and P E Greenberg
January 1998, Biotherapy (Dordrecht, Netherlands),
S N Finkelstein, and S L Huber, and P E Greenberg
June 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
S N Finkelstein, and S L Huber, and P E Greenberg
September 1998, British journal of cancer,
S N Finkelstein, and S L Huber, and P E Greenberg
August 1994, Blood,
Copied contents to your clipboard!